Gilead Sciences, Inc.
NASDAQ:GILD · NASDAQ Global Select
-$2.69 today
Vol 12.46M · Avg 6.78M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
37.5%
avg 32.5%
ROIC
21.5%
avg 14.4%
ROA
14.4%
avg 11.2%
Analysis
ROE is currently the strongest return metric at 37.5% versus its period average of 32.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel O'Day | Chairman & Chief Executive Officer | $8.70M | — | 61 | $626,346.00 | 0.05% |
Dietmar Berger | Chief Medical Officer | $5.92M | — | 57 | $46,928.00 | <0.01% |
Johanna Mercier | Chief Commercial & Corporate Affairs Officer | $3.44M | — | 56 | $124,234.00 | 0.01% |
Andrew D. Dickinson | Executive VP & CFO | $3.14M | — | 56 | $171,646.00 | 0.01% |
Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio | — | — | 64 | — | — |
Jacquie Ross | Senior Vice President of Treasury and Investor Relations | — | — | — | — | — |
Jyoti K. Mehra | Executive Vice President of Human Resources | — | — | 49 | — | — |
Stacey Y. Ma | Executive Vice President of Pharmaceutical Development & Manufacturing | — | — | 55 | — | — |
Bernard Fine | Vice President of Oncology & Franchise Head of Early Development | — | — | — | — | — |
Janet Dorling | Senior Vice President of Intercontinental Region & Global Patient Solutions | — | — | 51 | — | — |
Flavius Martin | Executive Vice President of Research | — | — | — | — | — |
Erin Burkhart | Senior VP, Controller & Chief Accounting Officer | — | — | 47 | $11,245.00 | <0.01% |
Keeley Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | — | — | 51 | $19,997.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
62
$76.38M
Net Sentiment
$76.38M
Net selling
Most Active
Mercier Johanna
23 transactions
1–10 of 62
Analysis
Insiders reported 0 buys worth $0.00 and 62 sells worth $76.38M over the last 12 months. That adds up to net selling of $76.38M. Mercier Johanna was the most active insider with 23 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +93.7% | +0.7% (15yr)3 analysts |
| Revenue | N/A | N/A | +49.8% | +1.2% (15yr)11 analysts |
| Net Income | N/A | N/A | +91.2% | -0.6% (15yr)11 analysts |
| EBIT | N/A | N/A | +76.9% | -5.1% (15yr)11 analysts |
Analysis
Recent growth has been strongest in EPS at +93.7% over three years. Forward estimates point to Revenue at +1.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$281.68B
Novo Nordisk A/S
NYSE:NVO
$191.04B
Amgen Inc.
NASDAQ:AMGN
$180.67B
Pfizer Inc.
NYSE:PFE
$143.65B
Danaher Corporation
NYSE:DHR
$125.39B
Stryker Corporation
NYSE:SYK
$119.04B
Bristol-Myers Squibb Company
NYSE:BMY
$109.86B
GSK plc
NYSE:GSK
$101.82B
Sanofi
NASDAQ:SNY
$101.57B
Boston Scientific Corporation
NYSE:BSX
$67.43B
Who manages GILD?
Gilead Sciences, Inc. (GILD) lists 13 active executives. The top listed executive is Johanna Mercier, Chief Commercial & Corporate Affairs Officer.
Are GILD insiders buying or selling?
Recent insider activity shows net selling of $59.27M.
Explore More
Continue the stock analysis
Jump to another research area for this company.